Parkinson’s disease (PD) is a neurodegenerative disease with a variety of clinical manifestations because of neuronal lost. For many years levodopa has been used to improve dopamine concentrations at the brain; however after a period of benefit, different limitations appear with levodopa use, including motor complications that can affect patients’ quality of life. Delaying the use for levodopa and the onset of motor complications is really important. OBJECTIVES: To compare the cost-effectivenes from a Mexican setting of the use of rasagiline monotherapy vs the use of pramipexole as treatment strategies in early PD. METHODS: We developed an economic Markov model to compare information on the effectiveness, utility and costs of the use of rasagiline and pramipexol over a 5 year period with six-month cicles. Model input data were obtained from Haycox et al model and validated in an expert panel of Mexican Neurologists.  Epidemiologic information was obtained from Mexican Health Minister. The expert panel was developed with a Delphi method to validate resource utilization, costs and utility of the disease. Costs were obtained from the Mexican Social Security Institute public lists. Effectiveness outcomes were time to levodopa, time to levodopa-induced dyskinesia and QALYs. RESULTS: Rasagiline was the dominant strategy. Evidence from the model suggests that in comparation with pramipexol, early use of rasagiline is associatied with a healt gain reflected in prolonged time to initiate levodopa by 23.57% through a gain of 0.796 levodopa-free years; delay in dyskinesia onset by 11.8% (0.49 years); and a 5.4% gain in QALY over a 5- year period. The cost per QALY by year found was MxP 33.400,00 wich is less than a Mexican GDP. Sensivity analyses confirmed that the model was robust. CONCLUSIONS: The model demostrates that rasagiline is a cost-effective alternative to pramipexol in the treatment of early PD in Mexico.